RxDoctor Payments Data

Christopher Thomas

Family · Louisville, KYNPI 1821676701

Payments from drug & device makers

$2,194in general payments, 2019–2025

Across 123 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$383
  • AbbVie$338
  • Novo Nordisk$281
  • Lilly USA, LLC$216
  • Takeda Pharmaceuticals U.S.A., Inc.$148
  • GSK$134
  • plus $694 from 15 others

What the payments were for

  • Food & beverage$2,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,194 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,494
Medicare patients
61
Services billed
112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide105$118,193
FarxigaDapagliflozin Propanediol103$84,409
OzempicSemaglutide55$56,131
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$31,919
JardianceEmpagliflozin32$31,466
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$30,258
EliquisApixaban29$24,327
JanuviaSitagliptin Phosphate11$13,430
TrulicityDulaglutide12$11,488
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,508
GlyxambiEmpagliflozin/Linagliptin11$6,605
Tresiba Flextouch U-100Insulin Degludec13$6,492
VascepaIcosapent Ethyl13$4,044
MupirocinMupirocin Calcium13$3,917
Albuterol Sulfate HfaAlbuterol Sulfate153$2,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$216$129,681117 claims
AstraZenecaFarxiga, Breztri Aerosphere$383$93,917118 claims
GSKAnoro Ellipta, Trelegy Ellipta$134$62,17795 claims
Novo NordiskOzempic$281$56,13155 claims
PfizerEliquis$56$24,32729 claims
AbbVieSynthroid$338$1,60832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →